These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
710 related articles for article (PubMed ID: 16343270)
1. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270 [TBL] [Abstract][Full Text] [Related]
2. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386 [TBL] [Abstract][Full Text] [Related]
3. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Baradari V; Huether A; Höpfner M; Schuppan D; Scherübl H Endocr Relat Cancer; 2006 Dec; 13(4):1237-50. PubMed ID: 17158768 [TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424 [TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398 [TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Pei XY; Dai Y; Grant S Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093 [TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
8. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280 [TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901 [TBL] [Abstract][Full Text] [Related]
10. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Ahn MY; Jung JH; Na YJ; Kim HS Gynecol Oncol; 2008 Jan; 108(1):27-33. PubMed ID: 17920664 [TBL] [Abstract][Full Text] [Related]
11. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934 [TBL] [Abstract][Full Text] [Related]
12. [Regulation of histone acetylation on the expression of cell cycle-associated genes in human colon cancer cell lines]. Chen YX; Fang JY; Lu J; Qiu DK Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):312-7. PubMed ID: 15059516 [TBL] [Abstract][Full Text] [Related]
13. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Romanski A; Bacic B; Bug G; Pfeifer H; Gul H; Remiszewski S; Hoelzer D; Atadja P; Ruthardt M; Ottmann OG Haematologica; 2004 Apr; 89(4):419-26. PubMed ID: 15075075 [TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Inoue H; Shiraki K; Ohmori S; Sakai T; Deguchi M; Yamanaka T; Okano H; Nakano T Int J Mol Med; 2002 May; 9(5):521-5. PubMed ID: 11956660 [TBL] [Abstract][Full Text] [Related]
15. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Facchetti F; Previdi S; Ballarini M; Minucci S; Perego P; La Porta CA Apoptosis; 2004 Sep; 9(5):573-82. PubMed ID: 15314285 [TBL] [Abstract][Full Text] [Related]
16. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020 [TBL] [Abstract][Full Text] [Related]
17. [Effects of sodium butyrate on proliferation of human gastric cancer cells and expression of p16 gene]. Shen WJ; Dai DQ; Teng Y; Liu J Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1192-6. PubMed ID: 18844115 [TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433 [TBL] [Abstract][Full Text] [Related]
19. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005 [TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Frønsdal K; Saatcioglu F Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]